What is a priority review voucher?

A priority review voucher is a coupon the FDA gives a company for getting a rare pediatric disease drug approved, and the company is allowed to sell it to a stranger. Four of them changed hands between April 2025 and June 2026 for between $150 million and $205 million. None of those four sellers redeemed the coupon themselves.

Congress built the thing to solve a problem it did not want to spend money on. A drug for a disease affecting a few hundred American children will not earn back the cost of the trials that prove it works, and no amount of encouragement changes that arithmetic. So the 2012 statute took the one thing the FDA controls and can give away without an appropriation, which is its own place in the queue, and made it into property. The subsidy gets paid by whoever buys the coupon. The Treasury pays nothing.

What the coupon actually buys

The statute is short about this. A voucher entitles the holder to priority review of a single human drug application, and priority review means FDA action "not later than 6 months after receipt." A standard review runs ten months from the same clock, so what the holder is buying is roughly four months of the agency's attention, once, on one application, after which the coupon is spent and gone.

Two features make it valuable to someone other than the company that earned it. The holder can be anyone: the sponsor "may transfer (including by sale) the entitlement to such voucher," and "there is no limit on the number of times a priority review voucher may be transferred before such voucher is used." And the buyer decides where to spend it. A four-month head start is worth very little on a drug with no competitor and a great deal on one racing a rival to the same market.

That gap is why the price is what it is. A small company with one approved rare disease product and nothing else near the finish line has no use whatsoever for four months of speed, while a large one with a launch contested by a rival working toward the same indication will pay nine figures for it.

What one is worth

Four sales, each from the seller's own release:

Zevra Therapeutics closed at $150 million on 7 April 2025, for the voucher it received when the FDA approved MIPLYFFA for Niemann-Pick type C. Fortress Biotech's subsidiary Cyprium closed at $205 million on 30 March 2026. Rocket Pharmaceuticals closed at $180 million on 28 April 2026 after the accelerated approval of KRESLADI. Denali Therapeutics signed at $195 million on 18 June 2026, following approval of AVLAYAH for Hunter syndrome.

For a company of the right size, this is not a line item. Zevra held $68.7 million in cash, equivalents and investments at 31 March 2025, and the same release puts the pro forma figure at $217.0 million once the voucher money is counted, which makes one coupon worth more than twice everything the company had in the bank. That is the reason these sales get announced on their own rather than buried in a quarterly report.

The number in the headline is not the number that reaches you

Fortress announced $205 million. In the second paragraph of that release, its chairman says Fortress "expects to receive over $100 million in proceeds from the transaction," because Cyprium is a majority-owned subsidiary rather than a wholly owned one. A shareholder who owns FBIO and reads the headline has overstated their share of the proceeds by roughly half, using a number the company printed correctly.

The smaller version of the same gap is in the Zevra release: $150 million gross, and "$148.3 million, net of fees." Both numbers are disclosed. Only one of them arrives.

Read for the verb, too. Zevra, Fortress and Rocket announced a closing. Denali announced a definitive agreement to sell, which is a signature rather than a wire transfer.

What the buyer pays the FDA on top

Redeeming a voucher is not free. The FDA sets the priority review user fee annually, and for fiscal 2026 it is $1,962,472, in addition to the ordinary PDUFA fee on the same application. The statute is blunt about getting it back: the Secretary "may not grant a waiver, exemption, reduction, or refund of any fees due and payable under this section."

Congress amended the rule on 3 February 2026 so the fee is now due on submission of the application rather than on the earlier notice of intent, a change the FDA wrote into the fee notice by correction in July.

Against a $195 million purchase price, two million dollars is rounding. It matters because it tells you the fee is not what makes the voucher expensive. Scarcity is.

The expiry nobody puts in the headline

The award authority has a hard stop. After 30 September 2029, the FDA may not award any new rare pediatric disease vouchers.

That date has moved seven times. The amendment history under the statute records the deadline going from 30 September 2020 to 11 December 2020, then 18 December 2020, then 30 September 2024, then 20 December 2024. Then it lapsed. Congress did not restore the authority until 3 February 2026, so for most of 2025 the program that produced these nine-figure sales sat expired, unable to award a single new voucher to any company whose drug happened to be approved in that window.

The tropical disease voucher, created five years earlier under a separate section, has no termination clause at all. The version everyone is chasing is the one that keeps expiring.

The limits of this

A voucher can be taken back. The FDA "may revoke any priority review voucher awarded" if the drug that earned it is not marketed in the United States within 365 days of its approval. The coupon is conditional on the company doing the thing the coupon was a reward for.

A voucher also buys review time, not an outcome. Six months of priority review can end in a complete response letter exactly as ten months can. The buyer is purchasing a date, not an approval.

And the buyers are mostly invisible. Three of the four sales above went to a counterparty the seller declined to name. The price is checkable. The buyer is not.

What to watch

• Whether the seller owns all of the entity holding the voucher. Fortress's $205 million became "over $100 million" one paragraph later. That gap lives in the release, not in the coverage.
• Gross against net. Fees came to $1.7 million on the Zevra sale.
• Agreement or closing. A definitive agreement is not cash received, and the release says which one it is.
• What the proceeds actually fund. Rocket described $180 million in "non-dilutive capital" and a cash runway extended into the second quarter of 2028. A voucher sale is a financing that costs shareholders no equity, which is why it usually appears in a release alongside a runway number.
• The Federal Register. The FDA must publish notice within 30 days of issuing a voucher, so whether a company holds one is a matter of public record rather than of management commentary.

This is analysis, not investment advice. Every figure above comes from the company's own release or from the statute and Federal Register notices linked at the point they are used.